Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) and its Japanese partner Eisai Co Ltd (TYO:4523) announced on Tuesday that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease has been selected by TIME as one of the 'Best Inventions of 2025' in the Medical and Healthcare category.

TIME's annual list of the Best Inventions features 300 innovations changing lives. To compile the 2025 list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields such as healthcare and AI. TIME then evaluated each contender on several key factors, including originality, efficacy, ambition, and impact.

Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for the clinical development, applications for market approval and commercialisation of Leqembi for Alzheimer's disease. BioArctic has the right to commercialise Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialisation in the region.